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ForeCastiNg outPatieNt PharmaCeutiCal exPeNditure For CaNCer 
treatmeNt iN germaNy
Schoch G.G.1, Blank S.1, Tamminga M.1, Steimle T.1, Stargardt T.2
1Techniker Krankenkasse, Hamburg, Germany, 2University of Hamburg, Hamburg, Germany
Objectives: To allow budgeting of pharmaceutical expenditure for cancer drugs 
in Germany, we forecasted future outpatient pharmaceutical expenditure for 
cancer treatment from the perspective of the statutory health insurance (SHI) for 
2016. MethOds: Based on data of the Techniker Krankenkasse (TK), a large German 
sickness fund with more than 8.2 million insured, we forecasted pharmaceutical 
expenditure for 12 cancer indications in 2016 (according to ICD-10: C16, C18-21, 
C22, C26.9/C49.9, C34, C43, C50, C56, C61, C73, C90, C91.1). To extrapolate results 
to whole SHI, we adjusted for differences in demographics of insured between 
TK and SHI using publicly available data, i.e. KM6 statistics. We also incorporated 
trends in membership to SHI. To assess the impact of new drugs, we obtained expert 
opinion by IMS Health on (a) the timing of drug launches in the German cancer 
market, (b) the expected prices of new drugs and (c) the extent to that new drugs will 
replace existing pharmaceuticals. For calculations, we assumed that newly launched 
drugs will reach on average a diffusion of 20% of their market potential until 
2016. Results: According to our model, SHI outpatient pharmaceutical expendi-
ture for these 12 cancer indications was million € 2,780 in 2012, i.e., 9.5% of total 
outpatient pharmaceutical expenditure. In 2016, we expect annual pharmaceutical 
expenditure for these indications to increase by 17.2% to million € 3,258. Of the 26 
new drugs identified to be launched until 2016,10 will at least partly replace existing 
pharmaceutical treatments. Thus, million € 526 of our budget estimate will be due to 
new drugs, € 2,650 million will be due to pharmaceuticals that were already launched 
in 2012 while € 82 million will be due to demographic change. cOnclusiOns: The 
expected increase in costs for cancer drugs are a financial challenge for German 
SHI. Whether benefit of new drugs and expected costs can be considered fair value 
needs to be investigated elsewhere.
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Budget imPaCt aNalysis oF everolimus For the treatmeNt oF 
hormoNe reCePtor Positive, humaN ePidermal growth FaCtor 
reCePtor-2 Negative (her2-) advaNCed Breast CaNCer iN KazaKhstaN
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Objectives: To determine the budget impact of everolimus (in combination with 
letrozole/anastrozole) as a second-line treatment for ER+ HER2-negative advanced 
and metastatic breast cancer in postmenopausal women in Kazakhstan. MethOds: 
A cumulative cohort model was developed to estimate the five-year costs associated 
with introducing everolimus to the Kazakh health care system, with two scenarios: 
“with everolimus” and “without everolimus”. Treatment-specific PFS and OS data 
were extrapolated from trial data using a Weibull function. It was assumed that 
data from the BOLERO-2 trial (everolimus+exemestane vs exemestane alone) were 
representative of everolimus+letrozole/anastrozole and letrozole/anastrozole used 
in the model. Per-patient drug, health state, adverse event costs were calculated. 
The per-patient costs were multiplied by the number of patients expected to receive 
each treatment according to predicted market share, which was split between 
everolimus+letrozole/anastrozole, letrozole/anastrozole alone, chemotherapy and 
tamoxifen. Results: The within-trial data from BOLERO-2 reported 17 month OS 
of 74.7% and 67.6% for everolimus+exemestane and exemestane alone, respectively. 
The utilities reported in BOLERO-2 (data available up to week 78) were 0.67 and 
0.70 for everolimus+exemestane and exemestane alone, respectively. The five year 
results demonstrate that the introduction of everolimus leads to a 12% increase in 
drug costs, a 2% reduction in pre-progression health state costs, a 1% increase in 
post-progression health state costs and a 2% reduction in adverse event costs. The 
net result is a 2% increase in total costs, from T16.97 billion to T17.389 billion over a 
period of five years. cOnclusiOns: The analysis estimated that, if everolimus were 
to be introduced to the Kazakh health care market for the treatment of ER+ HER2- 
advanced breast cancer, there would be a small impact upon overall health care 
expenditure. An increase in drug acquisitions costs was largely offset by a reduction 
in other health care costs due to improved disease management.
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Budget imPaCt aNalysis oF CyP2C19 geNotyPiNg to target 
voriCoNazole ProPhylaxis duriNg iNduCtioN-CoNsolidatioN theraPy 
iN aCute myeloid leuKemia (aml) iN the uNited states
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Objectives: To assess the impact of genotyping acute myeloid leukemia (AML) 
patients for CYP2C19*17 gene variant status prior to induction-consolidation therapy 
from the perspective of a United States (U. S.) payer. MethOds: Developed to aid 
U. S. payers regarding the budgetary impact of DNA genotyping, this model exam-
ines the predicted economic outcomes of a hypothetical cohort of 100 neutropenic 
AML patients under two alternatives: (1) standard voriconazole prophylaxis and (2) 
genotyping patients for targeted prophylaxis. Published allelic frequencies estimate 
27% of the general population may have at least one *17 allele. The presence of the 
CYP2C19*17 allele results in more rapid metabolism and clearance of voriconazole, 
which can lead to underdosing and ineffective prophylaxis on the standard regi-
men. The incidence of invasive fungal infection is 15% without effective prophylaxis 
and is reduced to 6.6% upon adequate prophylaxis. Targeted prophylaxis based on 
genotyping prescribes an alternative drug or higher voriconazole dose in patients 
with the *17 allele. Further model parameters were taken from published litera-
ture and 2014 CMS Laboratory Fee Schedule. Results: The average total cost of 
care for AML patients receiving standard versus targeted voriconazole prophylaxis 
was $46,795 and $46,385 per patient, respectively. In addition to the $410 saved 
per patient, the number of invasive fungal infections was reduced from 6.6 to 4.3 
tumumab. The current study aimed to evaluate the projected life years (LYs) and 
quality-adjusted LYs (QALYs) associated with ibrutinib, ofatumumab, and other 
therapies for treatment of CLL with prior therapy. MethOds: A health state model 
simulated treatment of a cohort of CLL patients who had received prior therapy. 
Patients were simulated to receive either ibrutinib or ofatumumab until death or 
disease progression, at which point they received subsequent treatment or best 
supportive care. Clinical inputs for ibrutinib and ofatumumab were informed by 
PCYC-1112 trial data (N= 391). Long-term follow-up data from PCYC-1102 and PCYC-
1103 trials (combined N= 101) was used in sensitivity analysis. Long-term OS and PFS 
were extrapolated from clinical trials to estimate survival outcomes. Utility were 
informed by published studies. Evaluation of ibrutinib versus other existing agent 
and emerging agents including idelalisib and ABT-199 was included in a sensitivity 
analysis. Long-term health outcomes were discounted by 3.5%. Results: Treatment 
with ibrutinib resulted in better health outcomes, incrementally increasing LYs 
by 0.63 and progression-free LY by 0.87 over a 5-year time horizon compared to 
ofatumumab, which lead to 0.47 incremental QALYs. In a 10 year time horizon 
analysis, ibrutinib increased LYs by 0.79. Ibrutinib was also associated with increased 
LYs and QALYs compared to other existing and emerging treatments. The model 
results are most sensitive to the approaches used to extrapolate OS. cOnclusiOns: 
Ibrutinib was demonstrated to yield better health outcomes for CLL patients with 
prior therapy compared to ofatumumab, largely driven by significant improvements 
in PFS and OS.
CaNCer – Cost studies
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Objectives: To estimate the budget impact resulting from the introduction of 
aflibercept for the treatment of metastatic colorectal cancer (mCRC) within drug 
program in Poland. MethOds: Analysis was performed in 3-year time horizon 
(2014-2016) from the public payer (NHF) perspective. Target population is defined as 
adult patients with mCRC that is resistant to or has progressed after an oxaliplatin-
containing regimen (including patients who experienced distant relapse within 
6 months of completion of oxaliplatin-based adjuvant therapy). Eligible patient 
population was estimated by compilation of following data: epidemiological studies, 
local market study, IMS data, survey among Polish oncologists. Market shares of dif-
ferent regimens (aflibercept 4 mg/kg +FOLFIRI, bevacizumab 10 mg/kg +FOLFOX-4, 
FOLFIRI) were projected based on the NHF data and experts’ opinion. Following cost 
categories were included: drug acquisition and administration (anti-VEGF, chemo-
therapy), diagnostics, monitoring and adverse events (grade 3-4). Results: With the 
introduction of aflibercept, estimated annual number of patients starting aflibercept 
treatment will be 90, 209 and 224 in year 2014, 2015 and 2016, respectively. Total 
annual expenditures in year 2014, 2015 and 2016 were calculated to be 39.3, 40.3 and 
41.2 million PLN in scenario without aflibercept, compared with 37.4, 34.9 and 35.0 
million PLN, respectively, with the introduction of aflibercept. In case of aflibercept 
reimbursement, the NHF would save 1.9 million PLN in year 2014, 5.3 million PLN 
in year 2015 and 6.1 million PLN in year 2016. cOnclusiOns: The introduction of 
aflibercept would result in savings for the NHF in Poland, mainly as a consequence 
of reduced pharmacological costs compared to bevacizumab.
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estimatiNg the eCoNomiC imPaCt oF soraFeNiB iN treatmeNt oF 
loCally reCurreNt or metastatiC, Progressive, diFFereNtiated 
thyroid CarCiNoma (dtC) that is reFraCtory to radioaCtive iodiNe 
(rai) treatmeNt
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Objectives: Sorafenib, a multikinase inhibitor, received Food and Drug 
Administration (FDA) -approval in 2013 for treatment of patients with locally 
recurrent or metastatic, progressive, radioactive iodine-refractory (RAI-r) dif-
ferentiated thyroid carcinoma (DTC). A budget impact model (BIM) was devel-
oped from a United States (US) payer perspective to estimate the costs of adding 
sorafenib to the set of available treatments in a hypothetical health plan in the 
RAI-r DTC population. MethOds: An Excel-based BIM evaluated costs of RAI-r 
DTC with other FDA-approved and compendia-recommended treatments using 
baseline and projected market shares. Clinical inputs included the prevalence of 
RAI-r, average monthly dosage, and average duration of sorafenib and other FDA-
approved and compendia-recommended treatments. Economic inputs for each 
treatment included the wholesale acquisition cost (WAC) per dose and hospital 
administration costs per month. A net per-month cost to the payer for sorafenib 
was $6,872. Laboratory testing costs were derived from product-specific package 
inserts and the Centers for Medicare & Medicaid Services (CMS) Physician Fee 
Schedule. Sorafenib market share was assumed to increase from 35% at baseline 
to 54% at 1 year, with shift from other treatments coming mostly (12%) from 
clinical trial/no treatment. The duration of sorafenib treatment was 11 months 
based the DECISION trial. Results: An estimated 25 patients with RAI-r DTC 
were eligible for treatment with sorafenib. Costs increased 25% ($282,467) or $0.02 
per member per month (PMPM) from baseline to 1 year post baseline. Sensitivity 
analyses, varying default inputs for duration of treatment (±2 months) and esti-
mated market share for sorafenib (±10%), showed greatest sensitivity to sorafenib 
market share (incremental total costs: $180,812–$384,122). cOnclusiOns: Our 
findings indicate that adding sorafenib to a hypothetical health plan’s formulary 
has a manageable budget impact of $282,467, or a PMPM increase of $0.02, given 
the small RAI-r DTC population.
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identified at IMSS and 631 at ISSSTE, 2,570 and 536 of them with NSCLC. A 4.2% ALK+ 
rate was assumed. Direct medical costs of standard treatment for LC were obtained 
from a published source. Cost for crizotinib was given by the manufacturer. All costs 
are expressed in 2014 USD ($1USD= $13MXN). Two scenarios are presented: 1) world 
without crizotinib, where all patients with LC are treated with standard treatment; 2) 
world with crizotinib, where patients with ALK+ advanced NSCLC are treated with 
crizotinib and all other LC patients are treated with standard treatment. Results: 81 
and 17 ALK+ advanced NSCLC patients were identified in IMSS and ISSTE, respectively. 
Total costs in a world “without” and “with” crizotinib using a one-year time horizon is 
$50.3 and $52.9 million, respectively, for IMSS. For ISSSTE, total costs were $10.5 versus 
$11.1 million. The combined incremental budget impact across both public health care 
institutions is 5.2%. cOnclusiOns: Crizotinib, the only drug approved for the treat-
ment of ALK+ advanced NSCLC patients has a minimal incremental budget impact on 
the overall expenditure within the two main Mexican public health care institutions.
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Budget imPaCt aNalysis oF everolimus Plus exemestaNe versus 
gemCitaBiNe Plus PaClitaxel aNd CaPeCitaBiNe Plus doCetaxel iN 
metastatiC Breast CaNCer PatieNts iN egyPt
Elsisi G.1, Saeed E.2, Elmahdawy M.3
1Ministry of Health, Faculty of Pharmacy Helwan University, Cairo, Egypt, 2Central Administration 
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Objectives: To estimate the budget impact of everolimus-exemestane versus the 
most commonly used regimens in the Egyptian practice; gemcitabine-paclitaxel 
and capecitabine-docetaxel for a health care plan that introduces everolimus 
for post-menopausal hormone receptor positive, human epidermal growth fac-
tor receptor-2 negative metastatic breast cancer (HR+, HER2-MBC) patients over 
three years. MethOds: Drug and medical budget impacts (2013 EGP) were esti-
mated over the first three years of the three drug regimens use from the health 
insurance perspective. Epidemiology data were used to estimate target popula-
tion size. The treatment data for MBC patients were obtained from published and 
nonpublished sources. The model considered 2 scenarios—without (pre) and with 
(post) everolimus-exemestane. Monthly medical costs were calculated for 
the pre- and post-progression phase. Results were considered on a per member 
per month (PMPM) basis to examine the relative impact on the plan. Deterministic 
sensitivity analyses were conducted. Results: In a real-world 6,055,902 targeted 
patients, 288,261 of them were found to be candidates for everolimus-exemestane 
regimen. For patients taking gemcitabine-paclitaxel and capecitabine-docetaxel 
regimens, the estimated incremental cost PMPM was LE3.00 and LE2.94 respec-
tively for each after three years. The estimated incremental cost PMPM for the 
gemcitabine-paclitaxel population was LE0.62, LE2.60 and LE5.77 for year 1, 2 and 
3 respectively while for the capecitabine-docetaxel population was LE0.59, LE2.54 
and LE5.70 for year 1, 2 and 3 respectively. The capecitabine-docetaxel results 
were most sensitive to the cost of everolimus while gemcitabine-paclitaxel results 
were most sensitive to the number of eligible patients. cOnclusiOns: Increased 
acquisition costs of everolimus-exemestane for HR+, HER2-MBC treatment 
are expected to be obviously offset by both the reduced number of progressed patients 
and the relatively small medical costs due to avoided adverse events of each of gem-
citabine-paclitaxel and capecitabine-docetaxel regimens. The expected budget impact 
of covering everolimus for this group of patients was relatively small.
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Buget imPaCt aNalysis oF rituximaB For ChroNiC lymPhoCytiC 
leuKemiC: the Case oF BraziliaN PuBliC health
Koury C.D.N.1, Nunes A.A.2, Nita M.1
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bAckgROund: Chronic Lymphocytic Leukemia (CLL) is a malignant disease incur-
able of the lymphoid system, that affects predominantly elderly, especially in 
Western countries. Your treatment when necessary is based on the administration 
of chemotherapy, with association of fludarabine plus cyclophosphamide (FC), the 
most widely used schema. Recently the addition of rituximabe, a monoclonal anti-
body has been associated with this scheme, known as FCR. Objectives: To elabo-
rate a budget impact analysis (BIA) of rituximab for chronic lymphocytic leukemic 
for help the decision making. MethOds: A BIA of association of fludarabine plus 
cyclophosphamide in SUS compared to rituximab with this scheme was performed. 
The analysis’ time horizon was 5 years, using a CLL prevalence of 4.4% and 25% of 
CLL refractory between them (1.634), considering an annual growth rate of 0.8143% 
and a market share of 25% and 75% according the classification of diagnosis and 
stage of Rai & Keating. The mean total rituximab dose considered was 375/mg/
m2, with an average personal weight and size of 70kg and 1,70m, which means 
681,75mg per cicle. All cost purchase prices and remission rate of rituximab (22%) 
and stand chemiterapy (9%) were obtained at one year trial in the onco-hematol-
ogy high complexity Clinical Hospital of the Faculty of Medicine of Ribeirão Preto 
HCFMRP / USP hospital measured in real 2012. Results: The budget impact of FC 
per year would be 38.7m reais ($17.5m) in the 1st year, considering 25% of target 
population, reaching approximately 135.3m reais ($60.9m) in 75% of patients. For 
RFC, the budget impact would be 97 million reais ($43.6m) in the 1st year, reaching 
340 million reais ($153m) in 75% of patients. cOnclusiOns: Treatment costs still 
impressive, considering that rituximab ’ values reach 2.5 times the clicle unit values 
of standart chemioperapy, fact that did not happen in other countries where they 
are already covered.
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real-world Costs oF laBoratory tests For NoN-small Cell luNg 
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Netherlands, 2VU University Medical Centre, Amsterdam, The Netherlands
by targeting prophylaxis based on patient genotype. The deterministic sensitivity 
analysis showed that the savings is most dependent on the incidence of invasive 
fungal infection, cost of treating an invasive fungal infection, and frequency of *17 
in the population. cOnclusiOns: Genotyping AML patients for CYP2C19*17 prior to 
induction-consolidation is expected to be cost-neutral or potentially cost-saving by 
reducing the incidence of invasive fungal infections compared to standard prophy-
laxis. These results may mitigate potential budgetary concerns, thereby reducing 
barriers to a test that can be clinically beneficial to AML patients.
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Budget imPaCt aNalysis oF the iNtroduCtioN oF New theraPeutiC 
ageNts For the treatmeNt oF metastatiC CastratioN resistaNt 
Prostate CaNCer (mCrPC) PatieNts aFter doCetaxel Failure iN the 
BraziliaN Private health system
Asano E., Vitale V.
Janssen-Cilag Farmaceutica, São Paulo, Brazil
Objectives: In the latest years several drugs demonstrated to increase survival 
in mCRPC patients post chemotherapy failure. However, issues remain related to 
the treatment sequencing of these drugs. The aim of this study is to estimate the 
budget impact of the introduction of enzalutamide in the Brazilian Private Health 
System. MethOds: A deterministic state transition budget impact model (BIM) 
was developed to estimate treatment costs of mCRPC patients after chemotherapy 
failure over a 3-year time horizon. Budget impact was estimated comparing a base-
line scenario including mandatory coverage drugs (abiraterone, cabazitaxel) with 
an alternative scenario including all treatment options (abiraterone, cabazitaxel 
and enzalutamide). Target population, dosing, duration of therapy and sequenc-
ing was based on scientific literature. Pharmaceutical direct costs were based on 
factory price, assuming parity price of enzalutamide and abiraterone. Univariate 
Deterministic sensitivity analysis was conducted to determine the impact of param-
eters on results. Results: The BIM estimates that a total of 5,789 patients will be 
treated in the next three years, with annual cost estimates in the baseline scenario 
of R$83,944,041 in year 1, reaching R$198,507,065 in year 3 of the simulation. The 
introduction of enzalutamide would incur a total increase in costs of R$16,649,325 
after 3 years. In deterministic sensitivity analysis, enzalutamide price, proportion of 
patients receiving additional treatment line and duration of therapy were the most 
important variables that impacted results, with the alternative scenario remaining 
more costly than the baseline scenario in all simulations, incurring additional costs 
ranging from R$6,634,955 to R$38,818,233. cOnclusiOns: Considering current 
available evidence regarding treatment sequencing, the introduction of enzaluta-
mide is expected to increase costs to the Brazilian Private Health System.
PCN47
Budget imPaCt model oF CePleNe® as maiNteNaNCe theraPy iN adult 
PatieNts with aCute myeloid leuKemia iN First remissioN
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Objectives: To assess the economic impact of Ceplene® with low-dose Interleukin-2 (IL-2) 
for the treatment of adult patients with Acute Myeloid Leukemia (AML) in first complete 
remission (CR-1) which previously received intensive chemotherapy in Spain. MethOds: 
A budget impact model was developed using the perspective of the Spanish 
National Health System with a 4-year time horizon. Ceplene®/IL-2 was compared 
with no treatment and an unrelated allogenic hematopoietic stem cell transplant 
(allo-HSCT). For both treatment options and no treatment, health care costs (EUR 
2013) including medical visits, hospitalisations, laboratory and diagnostic tests, 
prophylactic measures, treatment of complications and infections were consid-
ered. Average treatment costs per patient up to a maximum of three years were 
estimated for both treatment options and no treatment depending on the prob-
ability of overall survival without or with a relapse, and death without relapse, as 
well as the duration until relapse or death without relapse during this period. Total 
annual health care costs were estimated based on the annual per patient cost, the 
target population, and the market shares associated with each option, before and 
after the introduction of Ceplene®/IL-2. Results: Patients eligible for Ceplene®/
IL-2 were estimated at 1,502 in 2013 with a small increase up to 1,509 in 2016. 
The overall budget impact with the introduction of Ceplene®/IL-2, is estimated to 
decrease with € 674,149 and € 728,945 in 2014 and 2016, and an increase of € 202,322 
in 2015. Overall budget impact savings over the period 2014-2016 are estimated at 
€ 1,130,894. cOnclusiOns: The introduction of Ceplene®/IL-2 as maintenance therapy 
supposes savings in the budget impact for the treatment of AML patients in CR-1 in Spain. 
Ceplene®/IL-2 is expected to fulfil a direct medical need for patients not eligible or having 
an unfavourable profile for an unrelated allo-HSCT receiving no treatment, and those who 
received an unrelated allo-HSCT with unfavourable prognostics.
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Budget imPaCt aNalysis oF the use oF CrizotiNiB For NoN-small Cell 
luNg CaNCer aNd alK+ mutatioN iN the two maiN PuBliC health Care 
iNstitutioNs iN mexiCo
Guirant-Corpi L., Muciño-Ortega E.
Pfizer S.A. de C.V., Ciudad de México, Mexico
Objectives: Standard treatment for lung cancer (LC) in Mexico is chemotherapy. 
Crizotinib is the only therapy approved for patients with ALK+ advanced non-small 
cell lung cancer (NSCLC), a low prevalence condition. This analysis aims to estimate 
the economic impact of using crizotinib for patients with ALK+ advanced NSCLC 
in the Mexican setting from public health care institution perspective. MethOds: 
A budget impact analysis with a one-year time horizon was developed to compare 
expected costs that the Mexican Social Security Institute (IMSS) and the Safety and 
Social Services for State Workers Institute (ISSSTE) public health care institutions 
would incur if they were to include crizotinib on their formularies. Using epidemiol-
ogy data from published sources, a total of 3,023 potential patients with LC were 
